TransCode completes phase 1a cancer trial with no dose-limiting toxicities

June 3, 2026 8:04 AM

TransCode Therapeutics Inc. (NASDAQ: RNAZ) completed its Phase 1a clinical trial for TTX-MC138, an experimental cancer treatment, meeting the primary ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found